Protocolized Weaning of High-Flow Nasal Cannula in Adult Patients
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRush University Medical Center
About this trial
High-flow nasal cannula (HFNC) is a type of oxygen therapy commonly used in adults with breathing problems. While HFNC can help patients avoid breathing tubes and improve oxygen levels, there is no standard method for deciding how and when to reduce and stop this therapy once a patient improves. In many hospitals, these decisions vary from clinician to clinician.
This study will compare usual care with a standardized step-by-step plan for reducing HFNC support. Eight hospitals will participate and will switch from usual care to the standardized plan at different time points during the study.
The main goal is to determine whether the standardized weaning plan increases the number of patients who can successfully stop HFNC within 5 days. The study will also evaluate how long patients remain on HFNC, whether they need additional breathing support, and how long they stay in the hospital.
The results may help develop clearer guidance for safely and efficiently stopping HFNC therapy.
Eligibility criteria
Qualifiers
Adult patients ≥ 18 years
Receiving HFNC for ≥12 hours
Patients using HFNC to avoid intubation
Post-extubated patients who develop acute hypoxemic respiratory failure, regardless of respiratory support device prior to HFNC use.
Disqualifiers
• Planned procedures requiring intubation
Hypercapnia (PaCO2 ≥ 45 mmHg)
Receiving extracorporeal membrane oxygenation (ECMO)
Receiving continuous aerosol therapy via HFNC (e.g., inhaled nitric oxide [iNO], epoprostenol, or continuous albuterol)
Trial design
Treatments tested in this trial
- Protocolized HFNC Weaning Strategy
- Usual Care HFNC Weaning
Treatment groups
2,000 Participants
are divided into 2 treatment groupsSponsors and collaborators
Rush University Medical Center
Lead sponsor
The First Affiliated Hospital of Xiamen University
Collaborator
First Hospital of China Medical University
Collaborator
Shanghai Zhongshan Hospital
Collaborator
Binzhou Medical University
Collaborator
First Affiliated Hospital of Chongqing Medical University
Collaborator
Changhai Hospital
Collaborator
Source ClinicalTrials.gov